Pricing Log in Create free account
Saturday 17 October 2026 Export URGN’s income statement to Excel — free account

Urogen Pharma

URGN Healthcare Biotechnology

Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 199.2%, EPS grew 73.3%, free cash flow grew 17.3% and total debt rose 56.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

34.56 2.05 −5.60%
Market cap
$1.8B
P/E
0.0×
Fwd P/E
−30.0×
Dividend yield
—
F-score
2/9
Altman Z
−5.16
Beneish M
−1.42
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 4.77
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 — — 2 — — 1 2 1 1 2 1
Insider Ownership 17.63%

Capital & Financial Ratios $m

Market Cap 1,790.00
Revenue 188.73
Net Income (97.64)
Free Cash Flow (159.13)
Net Debt 82.37
Current Ratio 3.80 (at or above 1.5: strong)
Debt/Equity (1.45) (negative: negative equity)
P/E ratio 0.00
Fwd P/E (30.00) (negative: loss-making)
P/S ratio 9.23
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 92.99% (at or above 15%: strong)
Next Y EPS Growth 1,223.70% (at or above 15%: strong)
Next Y revenue growth 193.47% (at or above 10%: strong)
Next 5Y EPS Growth 50.33% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 9.7×, against a ten-year median of 8.9×; over the ten years it ranged from 0.9× in 2022 to 812× in 2019.
P/S against its own 10 years 47.46%
10-year low 10-year high
EV/Sales against its own 10 years 53.98%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 138 238 122 109
Receivables 15 20 33 89
Inventory 6 9 16 25
Other — — — —
169 276 186 235
2023 2024 2025 Q'26
Payables 17 27 28 40
ST’ Debt — — — —
Other 4 8 5 8
31 46 46 62

Compound Annual Growth %

10y 5y 3y
Sales — 56.22% 19.49%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 51 72 — — —
’25 20 24 27 38 110
’24 19 22 25 25 90
’23 17 21 21 24 83
’22 14 17 16 18 64
’21 7 13 11 16 48
’20 — 0 3 8 12
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (45) (33) — — —
’25 (42) (40) (42) (38) (162)
’24 (32) (24) (28) (14) (97)
’23 (26) (20) (17) (13) (76)
’22 (24) (24) (18) (22) (88)
’21 (27) (19) (18) (20) (85)
’20 (36) (24) (25) (21) (106)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (45) (33) — — —
’25 (42) (40) (42) (38) (163)
’24 (32) (24) (28) (14) (97)
’23 (26) (20) (17) (13) (77)
’22 (24) (24) (18) (22) (88)
’21 (28) (19) (19) (20) (86)
’20 (36) (24) (26) (21) (107)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.47) (0.28) — — —
’25 (0.92) (1.05) (0.69) (0.54) (3.19)
’24 (0.97) (0.91) (0.55) (0.80) (2.96)
’23 (1.30) (1.03) (0.68) (0.72) (3.55)
’22 (1.25) (1.18) (1.13) (1.22) (4.79)
’21 (1.17) (1.17) (1.35) (1.27) (4.96)
’20 (1.79) (1.44) (1.31) (1.38) (5.90)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — 13.01 36.95 20.72 13.12 8.68 4.85 7.60 10.26 3.42

Analyst estimates 2026–2028

Powerpack
High — 44.63 69.57 55.49 35.00 28.20 12.63 24.13 20.70 30.00
People
People Employees 33 46 78 173 187 195 200 201 235 291
Revenue/emp, $m 0.53 0.18 0.01 0.00 0.06 0.25 0.32 0.41 0.38 0.38
Income, $m
Income, $m Revenue 18 8 1 0 12 48 64 83 90 110
Gross margin, % 99.84 92.65 (59.84) 100.00 91.45 89.27 88.11 88.68 90.18 88.66
EBT (2) (20) (76) (105) (125) (109) (108) (98) (124) (153)
EBT margin, % (11.07) (244.93) (6,696.10) (584,144.44) (1,060.34) (227.66) (167.86) (118.87) (137.22) (139.74)
Net income (2) (20) (76) (105) (128) (111) (110) (102) (127) (153)
Depreciation 0 0 0 0 1 1 0 0 (3) (2)
Per share, $
Per share, $ Revenue 7.60 0.84 0.07 0.00 0.54 2.15 2.82 2.87 2.11 2.28
Earnings (0.84) (2.14) (4.80) (5.12) (5.90) (4.96) (4.79) (3.55) (2.96) (3.19)
Cash flow 1.82 (0.98) (2.37) (3.46) (4.86) (3.80) (3.84) (2.65) (2.26) (3.38)
Capex (0.30) (0.03) (0.04) (0.02) (0.06) (0.03) (0.01) (0.01) (0.01) (0.01)
Free cash flow 1.52 (1.01) (2.41) (3.48) (4.92) (3.83) (3.85) (2.66) (2.26) (3.38)
Book value 7.07 7.05 5.72 8.78 4.42 0.38 (3.92) (2.26) (0.21) (2.19)
Shares, m 2 10 16 21 22 22 23 29 43 48
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 0.00 601.39 1,030.15 33.21 4.42 3.06 5.30 5.05 10.26
P/B 1.98 5.48 7.53 3.80 4.07 25.26 0.00 0.00 0.00 0.00
EV/Sales 0.00 0.00 511.34 812.12 24.60 2.55 3.01 4.83 3.77 10.30
EV/FCF 21.38 (30.72) (15.22) (7.57) (2.71) (1.43) (2.21) (5.22) (3.51) (6.95)
Cash, $m
Cash, $m Operating cash flow 4 (10) (37) (71) (106) (85) (88) (76) (97) (162)
Capex (1) 0 (1) 0 (1) (1) 0 0 0 0
Free cash flow 3 (10) (38) (71) (107) (86) (88) (77) (97) (163)
Balance, $m
Balance, $m Working capital 19 67 89 129 94 92 105 138 230 140
Total debt — — — 3 1 0 98 99 122 122
Net debt (21) (73) (102) (145) (102) (90) (3) (39) (116) 0
Shareholders’ equity 16 69 90 180 96 8 (89) (65) (9) (105)
Returns, %
Returns, % ROA (9.15) (40.57) (84.48) (68.73) (79.22) (91.68) (85.98) (65.14) (54.68) (63.14)
ROIC 0.00 0.00 0.00 (193.80) 0.00 0.00 0.00 0.00 0.00 0.00
ROE (11.92) (47.16) (95.40) (77.77) (92.88) (211.55) 271.24 132.29 342.83 268.63
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Urogen Pharma vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MRVI Maravai LifeSciences Holdings, Inc. $1.8B — (loss-making) — (loss-making) +8.53% (above 0%: growing) n/m +127.57% (above 0%: growing) 40.14% (29.33%) Compare
ZYME Zymeworks Inc. $1.8B — (loss-making) 16.2× −90.58% (below 0%: shrinking) n/m −385.53% (below 0%: shrinking) (497.71%) (918.95%) Compare
PVLA Palvella Therapeutics, Inc. $1.8B — (loss-making) — (loss-making) −99.09% (below 0%: shrinking) n/m −136.38% (below 0%: shrinking) 100.00% 0.00% Compare
MESO Mesoblast Limited $1.8B — (loss-making) — −13.41% (below 0%: shrinking) n/m −89.23% (below 0%: shrinking) (353.35%) (909.40%) Compare
URGN Urogen Pharma $1.8B — (loss-making) — (loss-making) +199.22% (above 0%: growing) n/m +17.26% (above 0%: growing) 90.93% 0.15%
XNCR Xencor, Inc. $1.8B — (loss-making) — (loss-making) +17.46% (above 0%: growing) n/m −52.91% (below 0%: shrinking) 100.00% (72.37%) Compare
VIR Vir Biotechnology, Inc. $1.8B — (loss-making) — (loss-making) +19,582.54% (above 0%: growing) n/m +200.47% (above 0%: growing) 100.00% 30.75% Compare
SEPN Septerna, Inc. $1.8B — (loss-making) — (loss-making) +22,375.63% (above 0%: growing) n/m −9.01% (below 0%: shrinking) 100.00% (62.95%) Compare
BHVN Biohaven Ltd. $1.7B — (loss-making) — (loss-making) +131.43% (above 0%: growing) n/m +49.13% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $1.8B — — +13.00% — −30.96% 70.07% (46.14%)

All 614 Biotechnology stocks →

Urogen Pharma (URGN) key facts

  • Strength: Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024.
  • Urogen Pharma (URGN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, URGN traded at $34.56, a market capitalization of $1.8 billion.
  • Return on equity was 268.6% and debt-to-equity -1.45.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −5.16 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Urogen Pharma (URGN) Latest News

13 May

Impact 5 ·
stockrow.com/URGN · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com